SUMMARY. The 14C-triolein breath test, a recognised index of fat absorption, and the p-aminobenzoic acid (PABA) test, a 'tubeless' test of exocrine pancreatic function, have both been widely used in the diagnosis of malabsorption and exocrine pancreatic insufficiency. This study evaluates the potential of a combination of both tests in the investigation of fat absorption and exocrine pancreatic function. Combination of the tests has become technically feasible because of the introduction of high pressure liquid chromatography as the preferred method of analysis for PABA, and use of p-aminosalicylic acid (PAS) as the marker for PABA absorption and metabolism.
We studied 25 healthy subjects, II patients with exocrine pancreatic disease and 12 patients with gastrointestinal disease. The combined test identified subjects with reduced fat absorption and distinguished subjects with exocrine pancreatic insufficiency from those with an intestinal cause of fat malabsorption. The test could be completed in 7 h and had high patient acceptibility. These findings suggest that the combined 14C-triolein breath test and PABA test can be used as a non-invasive, I-day investigation of fat absorption and exocrine pancreatic function.
Additional key phrases: fat absorption; exocrine pancreatic function; high pressure liquid chromatography For many years the measurement of faecal fat has been regarded as the standard method for the assessment of fat absorption, despite the recognised disadvantages of possible incomplete collection of faeces, uncontrolled dietary intake of fat during the test, and the unpleasant nature of the test for both patients and hospital staff.
'4C-fat absorption breath tests were first described in the 1960s in an effort to remove the need for faecal fat measurement and a variety of 14C-Iabelled triglycerides have been used in such tests.'? 14C-triolein has been shown to give good discrimination between normal subjects and those with fat malabsorption when compared with a 3 day faecal fat assay adjusted for recovery of non-absorbable markers." Subsequent studies have confirmed the 14C-triolein breath test to be a reliable and highly reproducible index of fat absorption.i"
The PABA test of exocrine pancreatic function is a non-invasive investigation that is based upon the hydrolysis of the synthetic peptide N-benzoyl-tyrosyl-p-aminobenzoic acid (NBT-PABA) by chymotrypsin following oral Correspondence: Dr S C Fleming.
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administration with a test meal. Free paminobenzoic acid (PABA) released in the intestinal lumen is rapidly absorbed, metabolised within the liver and excreted in urine. Hence the urinary recovery of PABA may be used as an indirect index of luminal chymotryptic activity.
The PABA test as first described':" had two disadvantages. A low urinary PABA recovery may result from poor intestinal absorption, or poor renal excretion in addition to exocrine pancreatic insufficiency. These factors can be corrected for by administering free PABA on a separate occasion and estimating urinary recovery. The ratio of the two recoveries enables the calculation of a PABA excretion index (PEI)lO which allows for variation in intestinal absorption, hepatic metabolism and renal excretion. This, however, does require the test to be performed twice. 14C_PABA was introduced as a marker which can be administered simultaneously with NBT-PABA, allowing the PABA excretion index (PEl) to be derived within I day. II The other limiting factor in the use of the PABA test has been that of drug interference in the colorimetric assay for PABA. High pressure liquid chromatography (HPLC) is currently the preferred method of analysis because it is highly specific, allowing PABA to be easily separated from other aromatic arnines present in urine, and thus obviating drug interference problems. 12. 1J The introduction of HPLC has led to the replacement of 14C-PABA by p-aminosalicylic acid (PAS) as the marker of free PABA metabolism, since PAS has similar structural and pharmacokinetic properties to PABA. 14. 15 The PEl thus obtained correlates well with the results of the secretin/pancreozymin test in patients with exocrine pancreatic insufficiency.14 It has now, therefore, become feasible to combine the 14C-triolein breath test and the PABA test, using PAS as the marker of PABA metabolism, into a 1 day investigation of fat absorption and exocrine pancreatic function. This study reports the first evaluation of this combined test in healthy subjects, in patients with exocrine pancreatic disease, and in patients with gastrointestinal disease.
METHODS

Subjects
Twenty-five healthy volunteers, 18 men and seven women ranging in age from 20 to 50 years, with no history of gastrointestinal or pancreatic disease, served as a normal control group (Group I).
Eleven patients with exocrine pancreatic disease, eight men and three women, age range 31 to 75 years, mean 46·7 years, were studied (Group 2). Eight patients had chronic pancreatitis, two patients carcinoma of head of pancreas, and one patient a partial pancreatectomy for chronic pancreatitis. The diagnoses were confirmed by abnormalities of two or more of the following investigations: ultrasound, abdominal radiography, computerised axial tomography, endoscopic retrograde pancreatography, laparotomy and histology.
Twelve patients, five women and seven men, age range 37 to 77 years, mean 55·9 years, with documented gastrointestinal disease also underwent investigation (Group 3). The diagnostic categories were short bowel syndrome (three), Crohn's disease affecting the small intestine (one), untreated coeliac disease (seven) and systemic sclerosis (one).
Eleven unselected patients, six men, and five women, age range 28 to 64 years, mean 45·9 years, with a history of diarrhoea were also studied as part of their gastrointestinal investigation (Group 4). Final diagnoses, as assessed on Combined UC-triolein and PABA test 51 clinical, radiological and laboratory evidence were as follows: irritable bowel syndrome (five), lactose intolerance (two), gastric bypass for pyloric obstruction (one), sub-acute intestinal obstruction (one), infective diarrhoea (one) and vasculitis (one). No subject studied had evidence of renal impairment, based on the measurement of serum creatinine and urea concentrations, and all subjects had a fasting triglyceride concentration of < 2·0 mrnol/L. Fasting hypertriglyceridaemia is known to diminish the accuracy of the 14C_ triolein breath test."
Informed consent was obtained from the participants and the study was approved by the local medical ethical committee.
Protocol
The subjects fasted overnight and at the beginning of the test they were asked to empty their bladder, and to provide a pre-test urine sample. Two baseline breath samples were collected using methylbenzethonium hydroxide to trap 2 mmol CO 2.
4 The subjects were given orally 1 g NBT-PABA (bentiromide, Roche Products Ltd, UK) 360mg PAS, and 370kBq of 14C-triolein (Amersham International, UK) together with a 60 g fat meal, prepared as previously described." Further 2 mmol aliquots of breath CO 2 were collected at hourly intervals from 2 to 7 h and urine was collected for the whole 7 h period. Subjects remained at rest, and were allowed water or coffee without milk or sucrose to maintain an adequate urine output.
Analyses
Breath 14C02 activity was measured in each breath sample by liquid scintillation counting (LKB Instruments, UK) and compared with a standard obtained by dilution of the stock 14C_ triolein. For each sample (2 to 7 h) the percentage of administered radioactivity excreted per mmol of CO 2 was calculated. The percentage excretions at each time point were added to give a cumulative value," The volume of urine collected over the 7 h period was recorded and a 20 mL aliquot taken and stored at -20°C until analysis. The urine was subjected to alkaline hydrolysis at 110°C for I hour, which yields PABA, PAS, and the only breakdown product of PAS, 3-aminophenol. The concentrations of PABA, PAS and 3aminophenol (approximately 30% of the total PAS after 60 min hydrolysis) were determined by high pressure liquid chromatography. 17 The recoveries of PAS and 3-aminophenol were summed to give a total PAS recovery. The ratio of per cent PABA excretion to per cent PAS excretion, the PABA excretion index (PEl) was calculated. 14, 15 Statistical analysis was performed using nonparametric methods as the data were not normally distributed. The Mann-Whitney V-test was used to compare subject groups, and median values are reported. 
RESULTS
Evaluation of PAS as a pharmacokinetic marker for PABA The per cent urinary excretion of PABA and PAS were assessed in two healthy subjects when PABA was administered as both the free compound and as NBT-PABA, with PAS, on a total of five separate occasions. Urine was collected at hourly intervals. The overall PABA recoveries ( Fig. I) when given as the free compound and as NBT-PABA were very similar to that of PAS, although there was a small lag-phase in the excretion of PABA when administered as NBT-PABA. 
14C-triolein breath test and PABA test
The results in all subject groups are summarised in Table 1 and are represented graphically in Figs 2 and 3.
Healthy controls (Group 1)
The median cumulative 14C02 excretion in the normal subjects was 205 x 10-4 DID (range 131-321), which is in agreement with previous findings." The median urinary excretion of PABA in the normal subjects was 58·8% (range 40-78) and the PAS excretion was 57·0% (range 41-70). The median overall PEl in this group was 1-03 (0,75-1,49).
Subjects with exocrine pancreatic disease (Group 2)
The median cumulative 14C02 excretion in this group was significantly reduced at 15 x 10-4 DID (P < 0,001) compared with Group 1. The median 7 h urinary recovery of PABA was significantly reduced at 23·4% (P < 0,0001) compared with Group 1. In contrast, the 7 h PAS recovery (58'7%) was very similar to that of the subjects in Group 1 (P = 0,24) thus leading to a reduced PEl of 0-33 (P < 0'0001).
Subjects with gastrointestinal disease (Group 3)
These subjects had impaired 14C02 excretion (79 x 10-4%; P < 0,0001) compared with healthy controls. In this group PABA and PAS urinary recoveries were 52·1% and 54'7%, respectively, not significantly different from the control group, The median PEl in this group was 0-89. Compared with the exocrine pancreatic disease group (Group 2), there were significant differences between both the PABA recoveries (P = 0-015) and the PEls (P = 0,0001), but no significant difference between the PAS recoveries.
Subjects investigated for diarrhoea (Group 4)
This group of subjects had a median 14C02 excretion of 177 x 10-4 % which was not significantly different from that of the normal control subjects (P = 0-345). Urinary recoveries of PABA and PAS were 61·0% and 71'0%, respectively, also very similar to those of the control subjects. The median PEl of 0·85 was close to that of the healthy subjects, and no individual had a PEl less than 0-75.
DISCUSSION
The investigation of malabsorption is often a lengthy process, with the patient having to undergo time-consuming and sometimes invasive procedures which may require hospital admission. The introduction of 14C-breath tests has greatly simplified the diagnosis of malabsorption, and has high patient and staff acceptability. The investigation of exocrine pancreatic insufficiency has similarly benefitted from the introduction of 'tubeless tests' such as the PABA test which remove the need for duodenal intubation. Clearly a combination of both bests represents a significant advantage in that it is possible to differentiate between pancreatic and mucosal causes of malabsorption in a single day.
In previous studies several types of test meal have been administered concomitantly with NBT-PABA and PAS, and therefore it was important to assess PABA and PAS excretion when given with the 60 g fat test meal that we have previously used with the 14C-triolein breath test." The results obtained in our two healthy subjects (Fig. I) are in good agreement with previously published findings" in that PAS excretion closely followed that of free PABA. There is a small lag phase in the excretion of PABA when given as NBT -PABA and this has been attributed to the extra time required for hydrolysis of the peptide bond, to variation in the rate of gastric emptying, and to variation in luminal pH. IS. 18 In healthy subjects (Group 1) 14C02 excretion and urinary recoveries of PABA and PAS were in good agreement with published findings. 4,14.ls.17 Five of the control subjects, however, did have PABA and PAS recoveries between 40% and 50% which are a little lower than previously reported. 14,IS.17 This may be explained by slower gastric emptying, as we used a 60 g fat meal rather than Lundh test meal, which contains only 6% (wjv) fat, when orally administering NBT-PABA and PAS. Therefore we selected 40% as the lower limit of our reference range for the excretion of both PABA and PAS. The PEl in the healthy subjects was 1·03 with a lower reference limit of 0'70, and these values are in close agreement with published data.l" IS, 17 Subjects with exocrine pancreatic disease (Group 2) had a significantly reduced median 14C02 excretion as did the individuals with gastrointestinal disease (Group 3), thereby indicating both groups had severely impaired fat assimilation. The '4C-triolein breath test is able to identify subjects with poor fat absorption, but is unable to differentiate those subjects with exocrine pancreatic insufficiency from individuals with poor intestinal absorption of fat. It is possible to use a two-stage triolein breath test with pancreatic enzyme supplements'S" to identify patients with exocrine pancreatic insufficiency, but the test needs to be performed twice, on separate occasions, and requires the ingestion of two doses of carbon-14. Similarly, the pancreolauryl test, which does not require the use of HPLC, can be utilised but it still has to be performed on two separate occasions. In the combined test, as described here, subjects with exocrine pancreatic disease (Group 2) had a low median 14C02 excretion coupled with a significant reduction in urinary PABA recovery and normal PAS recovery, thus leading to a reduction in the PEL These results are therefore consistent with a low luminal activity of pancreatic chymotrypsin and also presumably of pancreatic lipase, which explains the low excretion of 14C02 on the grounds of reduced intraluminal digestion of triglyceride, rather than poor intestinal absorption.
In contrast, the individuals with gastrointestinal disease (Group 3) had a low median 14C02 excretion with normal recoveries of both PABA and PAS of 52·1% and 54'7%, respectively, and a normal median PEl of 0·95. This implies that the low 14C02 excretion encountered is a result of poor intestinal absorption rather than low pancreatic enzyme activity, as the intestinal absorption of PABA is similar to that of PAS, resulting in a normal PEL In subjects with a mild impairment of fat absorption e 4 C0 2 excretion 60 to 140 x 10-4%) urinary recoveries of PABA and PAS are normal. In two of our patients with severe intestinal disease C 4 C0 2 excretion < 60 x 10-4%) PABA and PAS recoveries were reduced in parallel, and it is likely that it requires a severe reduction in intestinal absorptive capacity before the absorption of PABA and PAS is impaired, as such small doses are employed in the PABA test. It is therefore important not to rely on PAS recovery alone as an indicator of impaired absorption. Difficulties in the interpretation of the combined 14C-triolein breath test and PABA test may arise in the patient who has both exocrine pancreatic insufficiency and a severe impairment of intestinal absorption. In this situation a pattern of results will be found similar to subjects who have a severe intestinal malabsorption alone, and therefore one will need to undertake further investigations to correctly identify this type of patient.
The II subjects with diarrhoea (Group 4) all had results that were within our normal reference range. The combined 14C-triolein breath test and PABA test is therefore able to distinguish subjects with poor fat digestion or absorption from those individuals who had another cause for their diarrhoea. In the small group of subjects studied there were no false positive results, and this indicates that the individual tests when used in combination retain their high specifici ty3, 4, 7, 15, 21 The combined test is simple to perform, is well tolerated by patients, and is easily completed within I day. It is a relatively inexpensive test in comparison to duodenal intubation tests, as the total cost of investigating each patient is approximately £70. The use of a carbon-14 isotope in this test precludes its use in children and' pregnant women. However, a combination of the D-xylose and PABA test can be used in such circumstances." As a result of this preliminary evaluation we believe that the combined 14C_ triolein breath test and PABA test has a role to play in the diagnosis of malabsorption and exocrine pancreatic insufficiency. The combined test should also be of use in determining the efficacy of pancreatic enzyme replacement therapy.
